The lack of potent Ras and c-Myc inhibitors and the acquirement of drug resistance make ERK3, ERK4, and MK5 attractive targets for therapeutic drugs in tumours with perturbed RAS, RAF or c-MYC activity. This evidence concerns the gene MAPK6 and neoplasm.